Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.

Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM.

Cancer Causes Control. 2010 Aug;21(8):1297-303. doi: 10.1007/s10552-010-9557-y. Epub 2010 Apr 10.

2.

Serum vitamin D concentration and prostate cancer risk: a nested case-control study.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team.

J Natl Cancer Inst. 2008 Jun 4;100(11):796-804. doi: 10.1093/jnci/djn152. Epub 2008 May 27.

3.

Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer.

Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, Giovannucci E.

PLoS One. 2011 Apr 6;6(4):e18625. doi: 10.1371/journal.pone.0018625.

4.

In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer.

Wong YY, Hyde Z, McCaul KA, Yeap BB, Golledge J, Hankey GJ, Flicker L.

PLoS One. 2014 Jun 20;9(6):e99954. doi: 10.1371/journal.pone.0099954. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109511.

5.

Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.

Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL.

Cancer Epidemiol. 2013 Oct;37(5):666-70. doi: 10.1016/j.canep.2013.07.005. Epub 2013 Aug 20.

6.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1484-93. doi: 10.1158/1055-9965.EPI-13-1340.

7.

Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E.

J Natl Cancer Inst. 2012 May 2;104(9):690-9. doi: 10.1093/jnci/djs189. Epub 2012 Apr 12.

8.

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J.

PLoS Med. 2007 Mar;4(3):e103.

9.

Vitamin D deficiency predicts prostate biopsy outcomes.

Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, Nadler RB, Kozlowski JM, Perry KT, Kajdacsy-Balla A, Kittles R.

Clin Cancer Res. 2014 May 1;20(9):2289-99. doi: 10.1158/1078-0432.CCR-13-3085.

10.

Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E.

Cancer Causes Control. 2004 Apr;15(3):255-65.

PMID:
15090720
11.

Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM.

Cancer Causes Control. 2012 Nov;23(11):1865-73. doi: 10.1007/s10552-012-0052-5. Epub 2012 Aug 28.

PMID:
22926301
12.

A prospective study of calcium intake and incident and fatal prostate cancer.

Giovannucci E, Liu Y, Stampfer MJ, Willett WC.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):203-10.

13.

Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study.

Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1850-60. doi: 10.1158/1055-9965.EPI-11-0403. Epub 2011 Jul 22.

14.

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study.

Gilbert R, Bonilla C, Metcalfe C, Lewis S, Evans DM, Fraser WD, Kemp JP, Donovan JL, Hamdy FC, Neal DE, Lane JA, Smith GD, Lathrop M, Martin RM.

Cancer Causes Control. 2015 Feb;26(2):205-18. doi: 10.1007/s10552-014-0500-5. Epub 2014 Dec 9.

15.

Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men.

Cauley JA, Parimi N, Ensrud KE, Bauer DC, Cawthon PM, Cummings SR, Hoffman AR, Shikany JM, Barrett-Connor E, Orwoll E; Osteoporotic Fractures in Men (MrOS) Research Group.

J Bone Miner Res. 2010 Mar;25(3):545-53. doi: 10.1359/jbmr.090826.

16.

Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.

Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):121-6.

17.

Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM.

Int J Cancer. 2012 Sep 1;131(5):1187-96. doi: 10.1002/ijc.27327. Epub 2011 Dec 21.

18.

Serum and dietary vitamin D and cardiovascular disease risk in elderly men: a prospective cohort study.

Messenger W, Nielson CM, Li H, Beer T, Barrett-Connor E, Stone K, Shannon J.

Nutr Metab Cardiovasc Dis. 2012 Oct;22(10):856-63. doi: 10.1016/j.numecd.2010.10.019. Epub 2011 Apr 3.

19.

Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study.

Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D.

Cancer Res. 2012 Mar 1;72(5):1190-8. doi: 10.1158/0008-5472.CAN-11-2950. Epub 2012 Jan 9.

20.

Vitamin D receptor protein expression in tumor tissue and prostate cancer progression.

Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E.

J Clin Oncol. 2011 Jun 10;29(17):2378-85. doi: 10.1200/JCO.2010.30.9880. Epub 2011 May 2.

Items per page

Supplemental Content

Write to the Help Desk